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Abstract
Background: Pre-pandemic development of an inactivated, split-virion avian influenza vaccine is challenged by the lack of
pre-existing immunity and the reduced immunogenicity of some H5 hemagglutinins compared to that of seasonal influenza
vaccines. Identification of an acceptable effective adjuvant is needed to improve immunogenicity of a split-virion avian
influenza vaccine.
Methods and Findings: Ferrets (N=118) were vaccinated twice with a split-virion vaccine preparation of A/Vietnam/1203/
2004 or saline either 21 days apart (unadjuvanted: 1.9 mg, 7.5 mg, 30 mg, or saline), or 28 days apart (unadjuvanted: 22.5 mg,
or alum-adjuvanted: 22.5 or 7.5 mg). Vaccinated animals were challenged intranasally 21 or 28 days later with 10
6 EID50 of
the homologous strain. Immunogenicity was measured by hemagglutination inhibition and neutralization assays. Morbidity
was assessed by observed behavior, weight loss, temperature, cytopenias, histopathology, and viral load. No serum
antibodies were detected after vaccination with unadjuvanted vaccine, whereas alum-adjuvanted vaccination induced a
robust antibody response. Survival after unadjuvanted dose regimens of 30 mg, 7.5 mg and 1.9 mg (21-day intervals) was
64%, 43%, and 43%, respectively, yet survivors experienced weight loss, fever and thrombocytopenia. Survival after
unadjuvanted dose regimen of 22.5 mg (28-day intervals) was 0%, suggesting important differences in intervals in this
model. In contrast to unadjuvanted survivors, either dose of alum-adjuvanted vaccine resulted in 93% survival with minimal
morbidity and without fever or weight loss. The rarity of brain inflammation in alum-adjuvanted survivors, compared to high
levels in unadjuvanted vaccine survivors, suggested that improved protection associated with the alum adjuvant was due to
markedly reduced early viral invasion of the ferret brain.
Conclusion: Alum adjuvant significantly improves efficacy of an H5N1 split-virion vaccine in the ferret model as measured
by immunogenicity, mortality, morbidity, and brain invasion.
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Introduction
Highly pathogenic avian influenza (HPAI) virus became widely
disseminated throughout Asian wild bird populations in 2004,
spread to Europe and Africa, and intermittently re-emerged in
domestic bird populations [1]. Bird-to-human transmission of
H5N1 strains remains inefficient, with approximately 500 H5N1
infections reported to the World Health Organization. In spite
of the few reported infections in recent years and the rarity of
human-to-human transmission, the high mortality rate of
approximately 60% among reported infections raises great
concern for pandemic potential if naturally recombinant avian
strains were to acquire efficient human-to-human transmission.
Vaccination is the most effective strategy to control the spread
of a pandemic influenza virus. Developing a pre-pandemic
vaccine for H5N1 strains presents a number of challenges
[2,3,4,5,6]. First, the world population has little prior exposure
to H5 strains, reducing the opportunity for cross-reactive
immunity. Second, the evolution of H5N1 strains from clade
0t oc l a d e9h a sb e e nr e l a t i v e l yr a p i do v e rw i d eg e o g r a p h i c
regions, demanding a level of heterotypic immunity from
stockpiled vaccines which is not necessary for seasonal vaccines.
Third, the logistics of rapidly protecting a large population
requires optimal dose-sparing design, including single dose
delivery with a stockpiled vaccine. Thus, immunogenicity of an
H5 vaccine must be optimized to achieve reduction of both
disease and transmission [7]. The vaccine composition and
production would ideally be identical to that for licensed
seasonal influenza vaccines by having low viral protein
concentration and used without adjuvant.
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vaccines appear to be immunogenic in humans and protective in
immunized ferrets [8,9]. Development of split-virion preparations
for seasonal vaccine is now preferred over the whole virion
formulations due to reduced reactogenicity yet retained immuno-
genicity among children [4]. There is, however, mounting
evidence that the immunogenicity of split-virion H5 vaccines
may be inferior to whole virion vaccine formulations. Two doses of
unadjuvanted split-viron H5N1 vaccine failed to induce homol-
ogous antibody and failed to protect ferrets against heterologous
challenge [10]. Likewise two immunizations of an unadjuvanted
split-virion vaccine (7.5 mg and 15 mg doses) from A/Vietnam/
1194/2004 (H5N1) strain failed to stimulate antibody or reduce
fever and viral shedding and provided only 50% protection against
lethal challenge [11]. In macaques, unadjuvanted split-virion
formulation failed to stimulate serum antibody [12]. In children
and adults, an unadjuvanted split virion H5N1 vaccine formula-
tion induced protective levels of antibody in only half of the
subjects [13,14].
Improvement in immunogenicity has been attained by addi-
tional booster doses [15], higher initial priming doses [13], or
administration with an immunological adjuvant. Several oil-in-
water based adjuvants have been tested for safety and efficacy in
humans [5]. Other vaccine strains have been previously shown to
be protective in the ferret model when administered in the
presence of other adjuvants [11,16]. Addition of an oil-in-water
adjuvant to a split-virion H5N1 vaccine in ferrets reduced
morbidity and viral shedding and completely protected against
mortality after a lethal heterologous strain challenge [11].
However, alum, an aluminum salt compound, is the only adjuvant
to be used without the addition of other components with a
vaccine licensed in the United States until 2009. Compared with
unadjuvanted vaccine, split-virion H5N1 vaccine administered
with alum to children resulted in higher titers of hemagglutination
inhibition antibody [14,17].
We used the ferret model to test whether the split-virion H5N1
Clade 1 vaccine formulation induced protective immunity without
and with an alum adjuvant.
Materials and Methods
Ethics Statement
All procedures were conducted under protocols approved by the
Institutional Animal Care and Use Committee (IACUC) at
Lovelace Respiratory Research Institute, and all facilities were
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC). To ameliorate
suffering, animals that were not expected to survive until the next
observation period moribund as described in the observation
section) were humanely euthanized.
Ferrets
Castrated ferrets (Mustela putorious furo, Triple F Farms, Sanger,
PA) aged 6–8 weeks were held for fourteen days for acclimation
and quarantine. Animals were pair- or triple-housed in plastic
bottom rabbit/ferret cages (Allentown Inc., Allentown, NJ) during
quarantine and vaccination period in the ABSL2 area and in
stainless steel cages (Allentown Inc, Allentown, NJ) modified to
have LEXANH doors to prevent intercage contact after viral
challenge. During the live virus exposure period, housing and
manipulation of animals was performed within a bioBubbleH
(bioBubble Inc, Fort Collins, CO) inside an ABSL3+ containment
area. Animals were screened for antibody to currently circulating
influenza A and B viruses prior to shipment from the supplier and
prior to their move into the ABSL3+ Facility, and only
seronegative animals were used. A total of 112 ferrets were
randomized (PathTox 4.2.2, Xybion, Cedar Knolls, NJ) into
groups of fourteen animals per vaccination group and divided
between two vaccine trials, hereafter designated as the ‘unadju-
vanted trial’ and the ‘adjuvanted trial’ (Table 1). Each vaccine
trial was divided into two cohorts with seven animals per
vaccination group during each of two exposure experiments. Six
additional animals from the alum-adjuvanted vaccine trial were
challenged six months after vaccination. An additional 40 ferrets
were vaccinated, challenged, and euthanized 2 days or 6 days after
challenge for the purpose of RNA transcriptional microarray
analysis; those results will be reported elsewhere.
Vaccines
H5N1 Monovalent Influenza Subvirion Vaccine (rgA/Viet-
nam/1203/2004) was provided by DMID/NIAID/NIH. Vac-
cines were provided at three concentrations of hemagglutinin
protein, specifically 90 mg/mL unadjuvanted (lot U10915C),
90 mg/mL unadjuvanted (lot UD07827), 90 mg/mL alum-adju-
vanted (lot UD07828), and 30 mg/mL alum-adjuvanted (lot
UD07826).
Vaccinations for the unadjuvanted trial used the 90 mg/mL
unadjuvanted (lot U10915C) diluted in physiological saline
immediately prior to vaccination to 30 mg, 7.5 mg, and 1.9 mg,
within 0.5 mL. The adjuvanted trial used 0.25 mL of the vaccine
as received to immunize the animals with 22.5 mg with (lot
UD07827) and without (lot U10915C) adjuvant, and 7.5 mg with
adjuvant. Control animals received either 0.5 mL or 0.25 mL of
physiological saline. Vaccinations were delivered by intramuscular
injection of the thigh with the other leg used for the second
vaccination.
Six or eight weeks (unadjuvanted or adjuvanted trial, respec-
tively) prior to intranasal challenge blood samples were collected
and animals received the first of two vaccinations. Ferrets were
vaccinated again three or four weeks later (unadjuvanted or
adjuvanted trial, respectively). Two vaccination schedules were
used to provide an additional test of the vaccine formulations
during the adjuvanted trial (the efficacy of vaccine with increased
time from vaccination to challenge). One week prior to challenge
Table 1. Summary of vaccine trial group allocations.
Trial
a Group Vaccine Dose (mg) Alum N Challenge Interval
b
U 1 30 No 14 3
U2 7 . 5 N o1 4 3
U3 1 . 9 N o1 4 3
U 4 Saline No 14 3
A 1 22.5 Yes 14 4
A 2 7.5 Yes 14 4
A 3 22.5 No 14 4
A 4 Saline No 14 4
A 5 22.5 Yes 2 24
A 6 7.5 Yes 2 24
A 7 22.5 No 2 24
a‘‘U’’ were animals in the Unadjuvanted Vaccine Trial. ‘‘A’’ were animals in the
Adjuvanted Vaccine Trial.
bChallenge interval is from the second vaccination until intranasal instillation of
virus.
doi:10.1371/journal.pone.0020641.t001
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animals were moved into ABSL3+ containment for acclimation
and pre-instillation observations and data collection.
Virus
Influenza virus A/Vietnam/1203/2004 (H5N1) (VN/1203)
was obtained as a low-passage stock from the Centers for Disease
Control and Prevention. This stock was passaged once in 10-day
embryonated chicken eggs to generate the master stock and once
again in eggs to generate the virus for all subsequent challenges
(Lot 03142007EP2.2). Aliquots of 0.5 mL to 1.0 mL were stored
at 280uC. After storage, the virus was determined to have a
concentration of 1.4610
8 plaque forming units (PFU)/mL,
5.8610
8 50% tissue culture infectious dose (TCID50)/mL, and
1610
8 50% egg infectious dose (EID50)/mL. Influenza A/
Vietnam/1203/2004 is a Risk Group 3 pathogen; all manipu-
lations were carried out in a BSL3/ABSL3+ containment
facility.
Intranasal Challenge
Ferrets were anesthetized by intramuscular injection with a
mixture of ketamine (KetasetH, Fort Dodge Animal Heath, Fort
Dodge, IA) and xylazine (AnaSedH, Lloyd, Shenandoah, IA) to
give 20 mg ketamine/kg and 4 mg xylazine/kg. Sedated animals
were tested for a sneeze reflex using the filled instillation syringe
and 20 ga catheter (SurfloH, Turmo Medical Co. Elkton, MD)
prior to drop wise instillation. Animals were held by the scruff with
the nares up and tilted slightly so as to have the inoculum flow
along the nasal turbinates. A total of one milliliter (500 mL per
nares), was used to challenge the animals with 10
6 PFU for the first
cohort of the first vaccine trial or 10
6 EID50 for the second cohort
of the first trial and both cohorts of the second trial. Back-titration
was performed on challenge stock and diluted instilled virus to
ensure consistent instillations between the five exposure cohorts.
Observations
Twice daily observations to assess animal health by determining
ocular discharge, nasal discharge, sneezing, coughing, stool
characteristics, and activity score. An activity score (0=alert and
playful, 1=alert but playful only when stimulated, 2=alert but
not playful when stimulated, and 3=neither alert nor playful
when stimulated) was obtained each time the ferrets were
observed. Daily weights and temperatures were also collected.
Temperatures were obtained from shoulder and hip implanted
microchips (IPTT-300 Implantable Programmable Temperature
and Identification Transponder; Bio Medic Data Systems, Inc,
(BMDS) Seaford, DE). Moribund animals were designated by any
one of the criteria: a temperature of less than 33.3uC, weight loss
equal to or greater than 25%, unresponsiveness to touch, self-
mutilation, paralysis, movement disorder, or respiratory distress.
Viral Load Samples
Nasal wash was performed by using a total volume of one
milliliter (0.5 mL/nares) of phosphate buffered saline (PBS)
containing 1% bovine serum albumin, 100 units penicillin/mL,
100 mg/mL streptomycin, and 0.25 mg amphotericin B/mL.
Samples werecollected prior to first vaccination, one week prior
to challenge, on days one through four post-instillation (pi), day
six, and prior to moribund or scheduled euthanasia.
Necropsy was performed to obtain tissue samples for virological
and histological examination on animals found dead, moribund,
or at 14 pi. Tissues were collected according to a standardized
protocol not based on gross pathology.
Tissues for viral load were a lavage of a lung lobe, lung (four
250 mg sections, a hilar and peripheral section each from a caudal
and a cranial lobe), 250 mg brain, 250 mg spleen, complete
tracheal bronchial lymph nodes, and two tracheal rings. Tissues
were placed into sterile PBS with one 5 mm stainless steel bead
(two beads for lung) and homogenized for four minutes using the
TissueLyser (QIAGEN, Valencia, CA). An aliquot of homogenate
was then used to isolate RNA for viral load quantification by qRT-
PCR. Remaining homogenate was used to determine viral load by
plaque.
Viral Load by Plaque Assay
Madin-Darby Canine Kidney (MDCK) cells were used to
quantify virus from samples by modified standard techniques [18].
Briefly, 6-well tissue culture plates were allowed to absorb 200 mL
of 10-fold diluted virus. After removal of virus, agarose overlay was
added and plates were incubated at 37uC for two days. Plaques
were read after fixation, removal of the agar and staining with
1.6% w/v crystal violet. Uninfected well of each plate was used as
a comparison for infected cells.
Viral Load by RT-qPCR
Samples were processed by the Kingfisher (Thermo Scientif-
ic). BCP (1-Bromo-3-chloropropane) was pipetted into the
sample (200 mli n t o1 0 0 0ml) vortexed for 10 seconds, and then
centrifuged at 13,000 rpm at 4uC for 10 minutes. The aqueous
layer was removed, placed in sampling tube and extracted by
the ‘‘Magmax Clear’’ protocol according to manufacturer’s
instructions.
Reverse transcription (RT) and quantitative PCR (qPCR) were
carried out in the same reaction. Samples were run using either the
ABI TaqMan One-Step RT-PCR Master Mix Reagents Kit
(Foster City, CA) or the Quantitect Virus Kit from Qiagen
(Valencia, CA). Samples prepared using the ABI kit were run in
triplicate on a 384 well plate. Each reaction contained 2.5–5 mlo f
RNA sample or no template control (NTC) (3 ml of RNA or NTC
and a total of 15 ml volume was found to be optimal), 33.3 nM
primer and 13.3 nM probe. Samples prepared using the Qiagen
kit were run using the same reaction volume as for the ABI kit, but
with and 333 nM primer and 80 nM probe. A standard curve was
run with an influenza M1 gene RNA in 10-fold increments
ranging from 10
9 to 10
1 copies/ml. The standard was prepared
using the blunt-TOPO vector from Invitrogen (Carlsbad, CA) and
the Mega-short-Script from Ambion (Austin, TX). Reactions were
set up using the Eppendorf epMotion 5075 robot. The sequence
for the forward primer is TTC ACA GCA TCG GTC TCA CAG
ACA, the reverse is TCC AGC CAT CTG TTC CAT AGC CTT
and the probe is/56-FAM/AAC AGA ATG GTG CTG GCT
AGC ACT/3BHQ_2/. Primer sequences were designed and
synthesized by Integrated DNA Technologies (IDT) (Coralville,
IA). RT was carried out for 209 at 50uC. PCR conditions were
95uC for 59, 40 cycles of 95uC for 150,6 0 uC for 450 on an ABI
7900HT Fast Real-Time PCR System machine. Data was
analyzed using ABI SDS 2.3 software. After manually setting the
threshold for the midpoint for each standard curve, the mean slope
was 23.5 for a mean of 93.07% efficiency, the mean y-intercept
was 41.5, and the mean r
2 was 0.998 for 18 plates.
Serology
Serological assays were modified from previously described
procedures [19,20]. Serum samples were inactivated by receptor-
destroying enzyme (Enka-Seiken, Tokyo, Japan) followed by heat
inactivation at 56uC for 30 minutes. Hemagglutination inhibition
(HI) was performed using horse red blood cells [21]. Titers of
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were determined by inoculating MDCK cells in 96-well plates with
serum that was incubated for one hour with 2000 TCID50/mL A/
Vietnam/1203/2004 combined with 2-fold diluted serum. Geo-
metric mean titers are reported, negative titer was denoted as 10.
Histopathology
Lung tissue and brain with olfactory bulbs were fixed in
buffered formalin. Sections were trimmed for histopathology from
the left cranial, right middle and right caudal lung lobes. Sampling
of brains included olfactory bulbs and coronal sections through the
entire brain at the frontal region, parietal region and cerebellum
with brainstem. Fixed tissues were paraffin embedded; 4 mm
sections were cut, stained with hematoxylin & eosin, and read by a
board certified veterinary pathologist (APG) without knowledge of
the vaccination history. Standard, subjective grading of lesions
inflammation was based on the severity of the change within
affected areas and the extent of tissue affected by the change.
Scores were:
0 (none)=essentially no tissue affected;
1 (minimal)=,1 to 5% affected,
2 (mild)=,6 to 25% affected,
3 (moderate)=,26 to 50% affected, and
4 (marked)=,50 to ,100% affected with a severe change.
Statistics
Statistical analyses were performed using GraphPad Prism
(version 5.03, GraphPad Software, Inc. La Jolla, CA). Serum
antibody response was analyzed by analysis of variance (ANOVA)
using the Bonferroni post-test. Survival proportions were tested
using the Log-Rank test. Morbidity by increasing activity score
was examined by using Fisher’s exact test. Viral load was
determined to be different by the repeated measure ANOVA.
Hematological measurements were analyzed by the t-test.
Results
Serum Antibody Response
Unvaccinated controls never had detectable neutralizing
antibody (Figure 1). Ferrets vaccinated without adjuvant,
regardless of vaccine dose, did not have detectable antibody prior
to challenge. Survivors vaccinated without adjuvant developed
serum neutralizing antibody, with titers after challenge ranging
from 160 to 3840 at day 14.
In contrast to unadjuvanted vaccine recipients, both adjuvanted
vaccines elicited antibody in all recipients prior to challenge
(Figure 1 B, D). Peak mean neutralizing antibody one week after
booster immunization was greater than 512, with only a modest
decrease during the 4 week interval prior to challenge. The two
non-surviving recipients of alum-adjuvanted vaccine had serum
titers within the same range as surviving ferrets. Neutralization
titers of survivors in the unadjuvanted dose groups were
significantly lower from each of the survivors in the alum-
adjuvanted vaccine groups fourteen days after challenge (ANOVA
with Bonferroni post-test, P,0.001).
Survival
All unvaccinated ferrets died by between day 3 and 9 pi.
Recipients of the unadjuvanted 30 mg dose of vaccine had a 64%
survival rate, while recipients of 7.5 mg and 1.9 mg doses had 43%
survival (Figure 2). Survival of the unadjuvanted 22.5 mg dose
group in the second trial was 0%, markedly lower than the similar
dose (30 mg) in the first trial. In contrast to unadjuvanted vaccine,
ferrets vaccinated with adjuvant had significantly higher survival of
93% in both groups (Log-Rank test, p,0.001).
Morbidity after viral challenge
Fever (.1uC above baseline) was documented in all ferrets of
unadjuvanted vaccine or saline groups beginning on day 1 pi and
was equivalent in duration (approximately 6 days) and amplitude
among all unadjvuanted groups (Figure 3, A & B). In contrast,
ferrets dosed with alum-adjuvanted vaccine did not develop fever
at any time after challenge.
Survivors in each of the three unadjuvanted vaccinated groups
lost less weight than non-survivors (Figure 3, C) with no
significant difference between the groups (p.0.05 ANOVA for
Repeated Measures). In contrast, ferrets vaccinated with adjuvant
did not show weight loss post-challenge (Figure 3, D).
Thirty-five of the 42 vaccinated ferrets in the unadjuvanted
vaccine trial experienced decreased appetite and liquid stool by
day 2 pi compared to 1 of 28 vaccinated with adjuvant in the
adjuvanted vaccine trial. Of the 56 ferrets vaccinated without
adjuvant including the saline controls, 24 displayed sneezing on
one or more days, typically beginning on day 3 pi compared to
only 4 of 28 vaccinated with adjuvant. By day 7 pi a decrease in
activity (score $1, Figure 4) was seen in 89%, 100%, and 83% of
survivors (30 mg, 7.5 mg, and 1.9 mg doses, respectively) in the
unadjuvanted vaccine trial. Non-survivors had further deteriora-
tion in activity one to two days prior to euthanasia for moribund
condition. Survivors in either vaccine trial did not experience a
decrease in activity beyond the score of 2. In contrast, only 46%
and 15% (22.5 mg with adjuvant and 7.5 mg with adjuvant,
respectively) of the surviving animals in the adjuvanted vaccine
trial displayed any changes in behavior (activity score $1).
Adjuvanted 7.5 mg dose group was significantly different, lower,
(Fisher’s exact test, p,0.01) than each of the surviving
unadjuvanted dose groups.
Hematology
By day 4 pi all ferrets in the unadjuvanted vaccine trial showed
a significant decrease in total white blood cell count (data not
shown), decrease in percentage of lymphocytes, and decrease in
the platelet count (t-test significant for each comparison at p,0.05)
(Figure 5, A &B). In contrast, the alum-adjuvanted vaccine
recipients did not have thrombocytopenia or lymphopenia
(Figure 5, C & D).
Viral load
Viral loads in unvaccinated control ferrets in both trials, and in
ferrets vaccinated with unadjuvanted 22.5 mg dose vaccine, was
high in all tissues and nasal washes when measured both by viral
culture (Figure 6; D, G, H) and RT-qPCR (Figure 7; D, G,
H). For all tissues there was no significant difference in titers
between the unadjuvanted vaccine group and the two unvacci-
nated control groups (p.0.5 for each comparison, ANOVA of
repeated measures). Groups vaccinated with 30 mg, 7.5 mg, and
1.9 mg of unadjuvanted vaccine also had similar viral loads
(Figure 6; A, B, C) and RT-qPCR (Figure 7; A, B, C). Among
non-survivors of unadjuvanted vaccine (total N=21), there were
no significant differences in viral loads in the nasal washes and
necropsy tissues, with the exception of the turbinate cultures.
Survivors had viral loads in nasal washes at day 2 and 4 pi not
significantly different from nonsurvivors and the unvaccinated
controls, indicating that intensity of upper tract infection did
not predict survival. Survivors in the unadjuvanted 30 mg group
did not have virus detected by culture or RT-qPCR in tissues
collected at necropsy on day 14 pi. In contrast, survivors in the
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RT-qPCR in culture negative tissues.
In the alum-adjuvanted vaccine groups, nasal washes had low
viral loads on day 2 and 4 pi (Figure 6 & 7; E & F), but culture of
all tissues of both survivors and nonsurvivors were negative,
suggesting that the addition of alum adjuvant was associated with
early suppression of upper tract infection. The one non-survivor in
the alum-adjuvanted 22.5 mg dose group had viral RNA detected
in respiratory tissues. However, all lavage and tissue cultures were
negative, suggesting a cause of death other than aggressive avian
influenza replication.
Brain tissue from non-survivors in unvaccinated and un-
adjuvanted vaccine groups contained high levels of virus by
culture and RT-qPCR. In contrast, all survivors had negative
cultures of brain tissue. Yet, 35% of the adjuvanted groups had
low levels of viral RNA in the brain. These viral load and clinical
observations are consistent with a major role of replicating virus
determining a fatal outcome.
Histopathology
Lungs of non-survivor animals revealed lesions characteristic
of avian influenza in the ferret, including atypical fibrinonecrotic,
neutrophilic pneumonia with hemorrhage often with intervening
regions of normal-appearing lung (Figure S1). Pulmonary
lesions tended to be focused in centriacinar regions, although
coalescence of pulmonary lesions to involve most of a lung lobe
was common in severely affected animals. Areas of inflammation
were characterized by focally extensive necrosis of parenchyma
with fibrin exudation, neutrophil and macrophage influx and
hemorrhage.
Figure 1. Hemaggutination inhibition and neutralizing antibody titers. Box plots denote the median (line in box), the 25
th and 75
th quartile
(ends of box), the mean (+), and the 95% confidence intervals (whiskers) with dots representing individual data points. The number (N) of samples
analyzed are shown below the x-axis under the number of samples that were below the limit of detection (BLD). At second vaccination is 3 or 4 weeks
after initial vaccination and 1 week prior to challenge is either 2 or 3 weeks after second vaccination.
doi:10.1371/journal.pone.0020641.g001
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to some degree, the olfactory bulb and the parietal lobe were
always affected in all non-survivors (Figure S2). Brains showed
lesions typical of avian influenza in this model, including
lymphohistiocytic and necrotizing meningoencephalitis, multifocal
in distribution with relatively discrete lesioned areas. Areas of
inflammation tended be intensely necrotizing with abundant
pyknosis and karyorrhexis of cells and increased cellularity with
lymphocytes, histiocytes and neutrophils. The meningeal compo-
nent of inflammation was often less than the encephalitis. Lesions
Figure 2. Survival proportions demonstrate adjuvant advantage. Saline vaccinated, control animals, from both vaccine trials are combined.
Asterisks (*) denotes a significant difference between survival rates of 93% (adjuvanted vaccine) and all others (Log-Rank test, p,0.001).
doi:10.1371/journal.pone.0020641.g002
Figure 3. Group mean temperature and weight change of vaccinated survivors. Data represent the mean of individual animal temperature
and weight change for each vaccinated group. The mean changes of the saline groups are combined from both cohorts to provide the same baseline
for both trials.
doi:10.1371/journal.pone.0020641.g003
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brain sections with decreasing severity in caudal sections.
Most of the survivors in both the unadjuvanted trial (15 of 19)
and the adjuvanted trial (24 of 26) had some degree of resolving
pneumonia at day 14 pi, indicating that challenged animals
developed pneumonia regardless of vaccination status (Figure
S3). The striking comparison was found in brain tissue (Figure 8).
Moderate brain inflammation and/or malacia (necrosis with loss
of brain tissue) was seen in all 19 survivors of the unadjuvanted
vaccine groups, despite the negative cultures (Figure 6). In
marked contrast only 2 of the 26 survivors in the alum-adjuvanted
vaccine groups had evidence of brain inflammation (p,0.001 by
Mann-Whitney rank test). The histopathologic findings of no or
minimal inflammation in olfactory bulb and brain of adjuvanted
trial survivors is consistent with either prevention of brain invasion
or subsequent viral replication within the brain.
Viral challenge six months after vaccination
Six months after vaccination with alum-adjuvanted vaccine,
neutralizing antibody was below detection limits in the four ferrets
tested (Table 2). After challenge, all 4 alum-adjuvanted vaccine
recipients survived to day 14 pi, whereas both recipients of
unadjuvanted vaccine were moribund by day 7 pi. All 6 animals
became febrile after viral challenge, although the alum-adjuvanted
vaccine ferrets developed fever on day six, compared to
unvaccinated animals developing fever by day two. Significant
weight loss of 24% occurred in one alum-adjuvanted vaccine
recipient whereas the other three recipients did not lose weight.
Virus was cultured from throat swabs from vaccine recipients of
unadjuvanted (days 1–4 and 6 pi) and 22.5 mg alum-adjuvanted
(days 1 and 3 pi). Although the numbers of ferrets studied were
small, the data suggest somewhat higher levels of morbidity
compared to ferrets challenged one month after the alum-
adjuvanted booster dose.
Discussion
We show here in the ferret model that a split-virion H5N1
vaccine elicited poor protective efficacy in the absence of adjuvant
(Figure 2). Inclusion of alum adjuvant not only protected ferrets
against a homologous lethal challenge, but also prevented most
measures of morbidity and histopathologic evidence of brain
invasion in surviving animals (Figure 8, S2). The relevance of
these findings to estimating avian influenza vaccine efficacy in
humans depends on three features of the test system: the ferret as a
test model, the immunogenicity of the H5 hemagglutinin in the
human compared to the ferret, and the effect of the adjuvant on
improving immunogenicity in the ferrets compared to the human.
The ferret model is considered to be the gold standard to test
vaccine efficacy, since the ferret disease mimics human disease
with respect to inhalation transmission, incubation period, tissues
infected, and histopathologic response to the influenza virus
[22,23,24,25]. The ferret has a density and array of sialic acid
receptors similar to humans [26,27,28], and therefore expresses
similar susceptibilities to infection by H5N1 strains [26,29]. Only a
few strains of H5N1 HPAI have been shown to be fatal in ferrets
[30]. The strain we used, A/Vietnam/1203/2004, has been
shown to be fatal in ferrets in intranasal doses from 10
1 to 10
7
EID50 [16,30,31,32]. The high level of virulence of the VN/1203
strain in ferrets [29] is attributable to multiple viral elements
including the multibasic amino acids in the HA hinge region and
replication competence expressed in the polymerase enzyme
complex [33].
The ferret serum antibody response to vaccination is similar to
that in vaccinated humans [24]. Modest immunogenicity inherent
in H5 hemagglutinins was seen in the initial immunogenicity trial
of the unadjuvanted VN/1203 split virus vaccine [13]. The highest
2-dose regimen elicited an MN GMT .1:40 in only 54% of
healthy adults, and the standard prime-boost dose with 15 ug
elicited MN titers at this level in only 22% of adults. Even after a
third dose of 15 ug, only 43% of vaccinees had an MN titer
.1:40, and only 27% had an HAI GMT titer .1:40 [15]. In an
early test of immunogenicity with a split-virion vaccine closely
related to the clade 0 Hong Kong/97 viruses, two doses of 30 mg
of unadjuvanted hemagglutinin protein seroconverted only a few
young adult volunteers [34]. A split-virion vaccine based on the
H5N1 clade 1 strain A/Vietnam/1194 was also poorly immuno-
genic without adjuvant [35].
Vaccination of ferrets with unadjuvanted split-virion vaccine
resulted in no serum antibody to H5 by the hemagglutination-
inhibition and microneutralization assays (Figure 1). Other
investigators have documented the failure to stimulate serum
antibody in vaccinated ferrets [2,10,11]. Immunization with two
7 mg doses of HA from an avian H5N3 strain failed to induce
antibodies to VN/1203 [36].
A wide array of experimental vaccines and adjuvants for
prepandemic and seasonal use have been shown to be immuno-
genic [37], but use in the near future will focus on proven
technologies. Aluminum salts are the only immunological
adjuvants approved in the United States [38]. Most immunoge-
nicity studies in humans have been done with aluminum
hydroxide (aluminum oxyhydroxide) although aluminum phos-
phate and alum (containing aluminum potassium disulfate) have
Figure 4. Group mean activity scores of vaccine recipients. Higher activity score indicates greater morbidity.
doi:10.1371/journal.pone.0020641.g004
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mediated as an antigen depot, induction of local inflammation
attracting antigen-processing cells to the site, and activation of the
Nalp3 inflammasome. Adjuvants likely mediate their effects
through a wide array of immune networks [39] although
aluminum salts have not yet been studied by network analysis.
In ferrets the addition of alum adjuvant has increased the
immunogenicity of the split virion vaccines. A single 7 mg dose of
whole virus H5N1 vaccine with alum adjuvant stimulated high
titers of neutralizing antibody and protected ferrets from lethal
challenge [16]. Likewise a single 15 mg dose of split virus vaccine
with aluminum phosphate adjuvant stimulated antibody and
completely protected ferrets [11]. Novel oil-based and polymer-
based adjuvants combined with single low-dose immunizations
have also been shown to stimulate antibody and provide
protection from lethal challenge [10,11,24]. Macaques immunized
with an alum-adjuvanted split-virus H5N1 inactivated vaccine
developed functional antibody titers and were fully protected
against challenge [12].
In healthy human adults the addition of aluminum salt
adjuvants to H5 vaccines have failed to consistently increase the
immunogenicity of split virion vaccines [38]. The highest dose of
vaccine with aluminum hydroxide adjuvant elicited the highest
antibody titers but there were no consistent differences between
adjuvanted and nonadjuvanted vaccinees overall [40]. Young
adults had a greater response to an adjuvanted A/VN/1203
vaccine only at one dose in a dose ranging study [41]and two other
studies found no adjuvant effect at any dose [42,43]. Children
developed ‘protective’ titers of clade-specific and cross-clade
neutralizing antibody after two 30 mg alum-adjuvanted doses of
Figure 5. Post-instillation lymphopenia and thrombocytopenia in vaccinated ferrets. Data represent the percentage change from pre-
instillation collection and samples available for analysis. Mean change and standard deviation (SD) are represented for each group.
doi:10.1371/journal.pone.0020641.g005
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culture was found, below limit of detection (LOD). Nasal wash (NW) samples were obtained on day 2, 4, and at necropsy (Nx). Tissue samples obtained
at necropsy were lung lavage (lavage), four sections of lung (lung), tracheal rings (trachea), turbinates (turbs.), and brain (cer. cort.).
doi:10.1371/journal.pone.0020641.g006
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20641Figure 7. Viral load by qRT-PCR nasal wash and tissue samples. Bars without error represent samples that were analyzed but where no viral
culture was found, below limit of detection (LOD). Nasal wash (NW) samples were obtained on day 2, 4, and at necropsy (Nx). Tissue samples obtained
at necropsy were lung lavage (lavage), four sections of lung (lung), tracheal rings (trachea), turbinates (turbs.), and brain (cer. cort.).
doi:10.1371/journal.pone.0020641.g007
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PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e20641Figure 8. Histopathology grading of brain lesions in survivors and non survivors. ‘‘Brain-Inflamation’’ represents sections of either
olfactory bulb or cerebral tissue with evidence of active and/or resolving inflammation. Tissues from moribund animals are denoted with an ‘‘M’’,
those from survivors (day 14 pi) are denoted with an ‘‘S’’; the number after the ‘‘M’’ or ‘‘S’’ indicated the number of ferrets in that group. The Y-axis is
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immunogenicity measured by serum H5N1 antibody alone may
not reflect protective efficacy, as has been shown in ferrets.
The reason for the disparate effects of aluminum adjuvants with
H5 split virion vaccines between ferrets and humans is not clear. A
reason may be pre-existing influenza immunity in older humans
negates the alum advantage seen in young immunologically naı ¨ve
seronegative ferrets. One distinct difference is the high frequency
of heterosubtypic immunity from previous exposure to seasonal
influenza that can provide some protection against a pandemic
strain [3], [13,44,45,46]. This heterosubtypic immunity has been
thought to be mediated largely by T-cells [47]. Broad-spectrum
neutralization targeting conserved epitopes on the hemagglutinin
molecule [45,48,49] and the neuraminidase enzyme [50] may
provide additional protection. Heterologous protection between
clades has been observed due to the use of an oil-in-water adjuvant
[10]. This suggests that the vaccine and adjuvant used for these
studies may provide heterosubtypic immunity.
Serologically negative ferrets can express heterosubtypic
immunity among seasonal strains [51]. A study of an unadju-
vanted whole virion clade 1 vaccine in ferrets found homologous
and heterologous protection even after a single low dose but these
ferrets had previous exposures to H3N1 influenza virus [16].
However, we and other investigators used ferrets seronegative for
HI antibody to circulating H3, H1 and type B strains both prior to
shipment and immediately prior to the priming dose of
vaccination. In addition, the pre-vaccination titers to H5 challenge
antigens were negative, indicating immunologically naı ¨ve animals,
within the sensitivity of the screening assays.
We found that some ferrets vaccinated without adjuvant with a
3-week interval had no detectable serum antibody at challenge yet
survived lethal challenge (Figure 1, 2). Other investigators have
documented protection against lethal challenge in vaccinated
ferrets in the absence of detectable neutralizing serum antibody
measured by the HAI and MN assays [2,10,11,36,52]. Multiple
mechanisms provide protection in the absence of serum antibody.
The relative importance of humoral and cellular immunity in
protection remains complex and difficult to predict [53]. We
speculate that the shorter challenge interval, 3-weeks, may have
assessed protection through an activated immune response. In
recipients of seasonal trivalent vaccine there is an inverse
relationship between neutralizing antibody titers and interferon-
gamma-producing cells [54]. Multiple assays will be needed to
construct a complete picture of the protective immune repertoire
in the ferret [4,55].
We observed here that vaccination without adjuvant afforded
some protection after a 3-week booster-challenge interval, but no
protection after a 4-week interval. No ferrets had detectable
antibody at the time of challenge. We speculate that decreasing
activated lymphocytes between 3 and 4 weeks explain the difference
in survival. Results from this study need to be verified in another
head-to-head comparison of booster-challenge intervals.
Increasing the booster-challenge interval of adjuvanted vaccine
from one month to six months resulted in continued protection
from mortality, yet without relief from weight loss, activity change,
cytopenias, and fever. These pilot data within these studies are a
beginning into the investigation of using similar vaccines for long
term protection in areas with continual human infections and not
just as near term protection prophylactic.
We examined ferret morbidity and the extent of inflammatory
disease in the lung and brain in vaccinated animals (Figure 8, S1,
S2, S3). Most ferrets vaccinated without adjuvant yet surviving to
day 14 post-challenge had evidence of moderate to severe
inflammation in both the lung and brain, indicating that extensive
infection had progressed in the individual animal before an
immune response was able to prevent death. Nasal wash results at
day 2 and 4 demonstrate the lack of viral suppression. Moreover,
all animals lost weight, experienced high fever, became anorectic,
and exhibited decreased activity. Even survivors exhibited marked
weakness, inactivity, thrombocytopenia, and weight loss 6 to 10
days after challenge before improving. The effect of the
unadjuvanted vaccine in moderating disease was apparent by
day 5 or 6 pi, late in the progression of disease and consistent with
the onset of T-cell mediated immunity [56]. In contrast, ferrets
that were vaccinated with alum adjuvant uncommonly showed
morbidity. Slightly decreased activity was observed in only six
animals and the lack of cytopenias, fever or significant weight loss
corroborated minimal morbidity.
Comparison of the striking differences in brain inflammation
between the unadjuvanted and alum-adjuvanted groups (Figure 8)
reveals insights into the mechanism of increased protection
mediated by the alum adjuvant. Reduction in spread of culturable
virus to the ferret brain had been noted previously in a study of
alum-adjuvanted whole virus vaccine [16]. In spite of diffuse brain
inflammation in the survivors of the unadjuvanted vaccine groups
all brain tissue cultures and viral RNA assays were negative,
consistent with relatively late reversal of viral replication in the
brain. Survivors of the alum-adjuvanted vaccine groups also had
negative cultures but had no or minimal levels of brain
inflammation. One reason for the lack of inflammation could be
the high levels of neutralizing antibodies one week prior to
challenge of the alum-adjuvanted vaccine groups. Yet, rather than
suppressing the systemic viral replication, we suggest that since
brain invasion appears to occur through sensory epithelial in the
the percent within each group (M or S) that was scored to each inflammation severity/grade. Grade 4 represents the most inflammation, whereas
Grade 1 represents the least inflammation. Grade 0 is clear and represents that no inflammation was found.
doi:10.1371/journal.pone.0020641.g008
Table 2. Summary of results from challenge six months after vaccination.
Vaccination Titer w-21
a Titer w-1
b .10% weight loss Fever Throat swab Survival
22.5 mg+Ad 1280, 806 ,20 0 of 2 Yes 2 of 2 2 of 2
7.5 mg+Ad ,20, 508 ,20 1 of 2 Yes 0 of 2 2 of 2
22.5 mg NoAd ,20, ,20 ,20 2 of 2 Yes 2 of 2 0 of 2
aw-21 is four weeks after second vaccination.
bw-1 is one week prior to intranasal challenge.
doi:10.1371/journal.pone.0020641.t002
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may be more important in preventing brain invasion.
The route of brain invasion and where protection may be
mediated is not yet clear. In mice infected intranasally with H5N1
virus, spread to the brain was strain-dependent [58] and viral
antigen appeared to enter via the mesenteric and myenteric plexi
of the enteric nervous system prior to appearing in brainstem
nuclei [59]. Direct injection of virus into the olfactory bulbs
resulted in productive infection of brainstem neurons [60].
Olfactory bulb infection occurs in ferrets inoculated intranasally
with high- and low- pathogenic H5N1 strains [30]. Ferrets infected
with 1 to 7 log10 PFU of A/Vietnam/1203/04 and A/Hong
Kong/483/97 strains had positive viral cultures in olfactory bulbs
24 h after intranasal inoculation and prior to appearance of virus
in spleens and brains [31] (unpublished data) , and has been
demonstrated by Shinya and colleagues [57]. In the turbinate
tissue at 24 h pi viral antigen localized primarily to the sensory
epithelial cells interfacing with neurons penetrating the cribiform
plate to synapse in the olfactory bulbs [31] (S Kunder et al,
unpublished observations). If brain invasion occurs within 24 h of
viral challenge, alum-adjuvanted vaccine may stimulate mucosal
immunity in the nasal turbinates to prevent early invasion.
Unadjuvanted vaccine may fail to stimulate sufficient mucosal
protection to prevent brain invasion, but in surviving ferrets
residual activated systemic immunity arrested viral replication in
the brain later in the course of disease.
In summary, the addition of alum adjuvant to a split-virion
H5N1 vaccine resulted in marked improvement in mortality and
morbidity. Further comparative studies of non-toxic adjuvants is
urgently needed with particular attention to the correlation of
protection to all humoral, cellular, and mucosal immune
components of the host. Such strategies to overcome the reduced
immunogenicity of split-virion avian influenza vaccines needs
continued evaluation in animal models as well as safety and
immunogenicity in humans.
Supporting Information
Figure S1 Representative pulmonary histopathology
from ferrets (all panels 4006 original magnification).
A) Normal lung for comparison (mild congestion of alveolar
capillaries is present). B) Saline recipient animal at 6 pi with
marked fibrinonecrotic pneumonia and loss of normal alveolar
airspaces. Note abundant mixed inflammatory cells within septae
and airspaces; pink, granular to fibrillar fibrin (f); hemorrhage; and
karyorrhectic debris (small arrowheads). C) Unadjuvanted vaccine
recipient at day 5 pi with similar fibrinonecrotic pneumonia and
loss of normal alveolar airspaces. Note abundant inflammatory
cells within septae and airspaces; pink, granular to fibrillar fibrin
(f); hemorrhage; and karyorrhectic debris (small arrowheads). D1)
Adjuvanted vaccine recipient at day 14 pi with perivascular
mononuclear inflammation (large arrowhead) with abundant
plasma cells as well as some septal infiltrates were often present
in animals recovering from infection and examined at 2 weeks.
(TIF)
Figure S2 Representative histopathology of olfactory
bulb of brain of ferrets (all panels 4006 original
magnification).Changes within olfactory bulbs were similar to
those occurring in the remaining brain, though severity of
the changes tended to diminish from rostral to caudal brain.
A) Normal olfactory bulb for comparison. B) Saline recipient at
day 6 pi with lymphohistiocytic and necrotizing meningoenceph-
alitis. Note general hypercellularity due to inflammatory infiltrates
and rarified areas due to spongiosus/edema (s). Eosinophilic
‘‘dead’’ neurons (arrowheads) are present along with abundant
karyorrhectic debris (arrows). C) Unadjuvanted vaccine recipient
at day 6 pi with similar changes to panel B. Note abundant
inflammatory cells, eosinophilic ‘‘dead’’ neurons (arrowheads),
spongiosus/edema (s), and abundant karyorrhectic debris (arrow).
D) Adjuvanted vaccine recipient at day 14 pi with focal malacia/
cavitating lesion within otherwise unremarkable olfactory bulb.
The contralateral bulb was within normal limits and animal was
clinically unremarkable. Moderate inflammatory/microglial cells
remain within the area of tissue loss, including gitter cells
(phagocytic cells containing lipid material from degenerating
nervous tissue). Unadjuvanted vaccinees surviving to 14 days
typically had similar, though generally larger and/or more
abundant foci.
(TIF)
Figure S3 Histopathology grading of lung lesions in
survivors and non survivors. ‘‘Lung –Acute’’ represents
sections displaying active, fibrinonecrotic inflammation. ‘‘Lung –
Subacute’’ represents sections found to have had evidence of prior
or resolving inflammation. Tissues from moribund animals are
denoted with an ‘‘M’’, those from survivors (day 14 pi) are denoted
with an ‘‘S’’; the number after the ‘‘M’’ or ‘‘S’’ indicated the
number of ferrets in that group. The Y-axis is the percent within
each group (M or S) that was scored to each inflammation
severity/grade. Grade 4 represents the most inflammation,
whereas Grade 1 represents the least inflammation. Grade 0 is
clear and represents that no inflammation was found. Each
vaccination dose is labeled A–H.
(TIF)
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